Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Relmada Therapeutics Inc (RLMD) PT Raised to $90 at Truist Securities
July 27, 2021 10:14 AM EDTTruist Securities analyst Joon Lee raised the price target on Relmada Therapeutics Inc (NASDAQ: RLMD) to $90.00 (from $75.00) while maintaining a Buy rating.
... MoreRelmada Therapeutics (RLMD) to Resume Trading at 8:30 a.m.
July 27, 2021 8:26 AM EDTRelmada Therapeutics (NASDAQ: RLMD) to Resume Trading at 8:30 a.m.
Relmada Therapeutics (RLMD) Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
July 27, 2021 7:35 AM EDTRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3... More
Relmada Therapeutics (RLMD) Halted, News Pending
July 27, 2021 7:25 AM EDTRelmada Therapeutics (NASDAQ: RLMD) Halted, News Pending
